Research foundation · First program launches 2026
Medicine that lasts.Prevention thateveryone can afford.
The World Peace & Prosperity Foundation is a youth-founded research foundation combining AI and drug discovery to build long-lasting, affordable preventive solutions for allergies, eczema, and other immune-driven disease.
- research programs
- 3
- research programs
- first program launch
- 2026
- first program launch
- pipeline & findings
- Open
- pipeline & findings
The problem
Immune-driven disease is common, chronic, and expensive to live with.
Allergies and eczema touch a third of American households. Care is mostly symptomatic, repeated monthly, and priced for those who can afford it. The pipeline that could change that takes a decade and billions of dollars per drug.
1 in 3
U.S. adults reported a seasonal allergy, eczema, or food allergy in 2021
Source: CDC / NCHS Data Brief No. 460 (2023)1 in 4
U.S. children reported a seasonal allergy, eczema, or food allergy in 2021
Source: CDC / NCHS Data Brief No. 459 (2023)$2.6B
estimated capitalized cost to bring one new drug to approval
Source: DiMasi, Grabowski & Hansen, J. Health Econ. (2016)Our approach
AI finds the candidates faster. We insist they be durable and affordable before anything else.
Prevent, don't just treat
Most immune-driven disease is managed symptom by symptom, year after year. We study the upstream drivers so care can start before the flare, not after.
Long-lasting by design
A solution that must be re-bought every month is a subscription, not a cure. We prioritize durable interventions: longer protection from fewer doses.
Affordable from day one
AI-guided discovery can cut years and hundreds of millions from the path to a candidate. We pass that efficiency on, so what we find can reach every family.
Research programs
Three programs, one open pipeline.
AI-Guided Target Discovery
Using machine learning over public immunology datasets to prioritize targets and candidate molecules for allergic and inflammatory disease, before a single wet-lab dollar is spent.
Program details →Durable, Affordable Therapeutics
Partnering with academic labs to move the strongest candidates toward long-acting, low-cost formulations designed for global access.
Program details →Community Health Data
Short, consented surveys and volunteer cohorts that capture how allergies and eczema actually show up in daily life, feeding real-world signal back into discovery.
Program details →Open Bench · Drug discovery school
We teach drug discovery to twelve-year-olds.
Drug discovery is taught to graduate students because the field assumes you need a lab. You no longer do. Open Bench is a free eight-unit course that takes a middle or high school student from “what is a disease” to a ranked list of real drug targets they produced themselves.
Every lesson plan is published. Every tool is free. Students who finish are trained to teach the next cohort, so the course outlives whoever wrote it.
Founders
A new generation is building the next medicine.
WPPF was founded by two brothers who saw, from hospital corridors and community kitchens, that prevention is a privilege it should not be. They are students. They are also already a track record.
Meet the founders →Roadmap
From first dataset to first candidate.
Foundation year
- Launch Program P-01: AI-guided target discovery over public immunology datasets.
- Pilot Program P-03: community health surveys with the first volunteer cohort.
- Complete 501(c)(3) determination and publish governance documents.
First results
- Publish the open discovery pipeline and first ranked target list.
- Sign the first academic lab collaboration under Program P-02.
- Release aggregate findings from the community cohort back to participants.
Toward durable, affordable candidates
- Advance one or more candidates into preclinical work with partner labs.
- Expand community cohorts beyond the United States.
- Establish an access-first licensing framework for anything the foundation helps discover.
Founding Partners · 2026
Fund the first year. Be named for all of them.
We are assembling the founding partners who will underwrite the 2026 program. Pledge now; giving instructions follow once our 501(c)(3) determination is issued.